Home  /  Resource Library  /  A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

ASH 2019: Results of a phase I/II study investigating the combination of Umbralisib, Ublituximab and Venetoclax for treatment of relapsed CLL.